Quanterix Corp
NASDAQ:QTRX

Watchlist Manager
Quanterix Corp Logo
Quanterix Corp
NASDAQ:QTRX
Watchlist
Price: 10.52 USD -1.22% Market Closed
Market Cap: 403.8m USD
Have any thoughts about
Quanterix Corp?
Write Note

Quanterix Corp
Total Current Liabilities

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Quanterix Corp
Total Current Liabilities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Total Current Liabilities CAGR 3Y CAGR 5Y CAGR 10Y
Quanterix Corp
NASDAQ:QTRX
Total Current Liabilities
$37.5m
CAGR 3-Years
0%
CAGR 5-Years
17%
CAGR 10-Years
N/A
Thermo Fisher Scientific Inc
NYSE:TMO
Total Current Liabilities
$14.6B
CAGR 3-Years
23%
CAGR 5-Years
20%
CAGR 10-Years
9%
Danaher Corp
NYSE:DHR
Total Current Liabilities
$7.3B
CAGR 3-Years
0%
CAGR 5-Years
4%
CAGR 10-Years
5%
Mettler-Toledo International Inc
NYSE:MTD
Total Current Liabilities
$1.2B
CAGR 3-Years
6%
CAGR 5-Years
10%
CAGR 10-Years
6%
Agilent Technologies Inc
NYSE:A
Total Current Liabilities
$1.9B
CAGR 3-Years
4%
CAGR 5-Years
-2%
CAGR 10-Years
1%
IQVIA Holdings Inc
NYSE:IQV
Total Current Liabilities
$7B
CAGR 3-Years
13%
CAGR 5-Years
14%
CAGR 10-Years
17%
No Stocks Found

Quanterix Corp
Glance View

Market Cap
403.9m USD
Industry
Life Sciences Tools & Services

Quanterix Corp. engages in the development of ultra-sensitive digital immunoassay platform that advances precision health for life sciences research and diagnostics. The company is headquartered in Billerica, Massachusetts and currently employs 460 full-time employees. The company went IPO on 2017-12-07. The firm is engaged in developing ultra-sensitive digital immunoassay platforms that advance precision health for life sciences research and diagnostics. Its platforms are based on its digital Simoa detection technology. Its Simoa bead-based and planar array platforms enable customers to reliably detect protein biomarkers at extremely low concentrations in blood, serum and other fluids. Its products include HD-X Analyzer, SR-X Biomarker Detection System, SP-X Imaging and Analysis System, and 2470 Arrayer. The company also supplies NF-Light antibodies and ELISA kits, which offer solutions for the detection of neurofilament light (Nf-L) for the development of therapeutics and diagnostics for neurodegenerative conditions. Its portfolio of available kits spans multiple therapeutic areas, including cardiology, infectious disease, inflammation, neurology, and oncology. The company provides services through its Simoa Accelerator Laboratory.

QTRX Intrinsic Value
16.45 USD
Undervaluation 36%
Intrinsic Value
Price

See Also

What is Quanterix Corp's Total Current Liabilities?
Total Current Liabilities
37.5m USD

Based on the financial report for Jun 30, 2024, Quanterix Corp's Total Current Liabilities amounts to 37.5m USD.

What is Quanterix Corp's Total Current Liabilities growth rate?
Total Current Liabilities CAGR 5Y
17%

Over the last year, the Total Current Liabilities growth was 18%.

Back to Top